Management of Vitamin D Deficiency Presenting with Bone Deformity

Initial Assessment and Diagnosis

The American College of Cardiology is not mentioned, however, the Endocrine Society recommends measuring serum 25-hydroxyvitamin D [25(OH)D] to confirm deficiency, with levels below 20 ng/mL (50 nmol/L) indicating deficiency and levels below 10-12 ng/mL indicating severe deficiency with high risk for osteomalacia and rickets 1
Obtain baseline serum calcium, phosphorus, alkaline phosphatase, and parathyroid hormone (PTH) to assess for hypocalcemia, hypophosphatemia, elevated alkaline phosphatase, and secondary hyperparathyroidism—the classical biochemical pattern of osteomalacia, as recommended by the National Institutes of Health 2
Check for hypocalcemia specifically, as severe vitamin D deficiency with bone deformity often presents with low serum calcium requiring careful monitoring during repletion to avoid rebound hypercalcemia, according to the Endocrine Society 3
Perform imaging studies including plain radiographs of affected bones to assess for pseudofractures (Looser zones), bone deformities, and fractures, and consider DXA scan to evaluate bone mineral density once vitamin D is repleted, as suggested by the National Osteoporosis Foundation 3

Administer 50,000 IU of cholecalciferol (vitamin D3) weekly for 8-12 weeks as the standard loading regimen for severe deficiency with bone manifestations, as recommended by the Endocrine Society 1
Prefer vitamin D3 (cholecalciferol) over vitamin D2 (ergocalciferol) because D3 maintains serum levels longer, has superior bioavailability, and is more effective with intermittent dosing schedules, according to the National Institutes of Health 1
For severe deficiency with symptomatic bone disease or levels below 10 ng/mL, extend treatment to 12 weeks rather than 8 weeks to ensure adequate repletion, as suggested by the Endocrine Society 1

Provide 1,000-1,500 mg elemental calcium daily in divided doses (maximum 600 mg per dose) to support bone mineralization and prevent hungry bone syndrome as vitamin D stores replete, as recommended by the National Institutes of Health 1
Administer calcium supplements with meals and separate from iron-containing supplements by at least 2 hours to optimize absorption, according to the Endocrine Society 1

Consider intramuscular vitamin D3 50,000 IU if oral supplementation fails or if the patient has documented malabsorption syndromes such as inflammatory bowel disease, celiac disease, pancreatic insufficiency, short bowel syndrome, or post-bariatric surgery status, as suggested by the American Gastroenterological Association 1
IM administration results in significantly higher 25(OH)D levels and lower rates of persistent deficiency compared to oral supplementation in patients with malabsorptive conditions, according to the National Institutes of Health 1

Recheck 25(OH)D levels at 3 months after completing the loading phase to allow vitamin D levels to plateau and accurately reflect treatment response, with a target level of at least 30 ng/mL for optimal bone health and anti-fracture efficacy, as recommended by the Endocrine Society 1
Monitor serum calcium and phosphorus at least every 3 months during treatment, and discontinue vitamin D immediately if corrected total calcium exceeds 10.2 mg/dL (2.54 mmol/L), according to the National Institutes of Health 1

Transition to maintenance dosing of 2,000 IU daily or 50,000 IU monthly after completing the loading phase and achieving target 25(OH)D levels above 30 ng/mL, as suggested by the Endocrine Society 1
For elderly patients (≥65 years), maintain at least 800-1,000 IU daily to reduce fall and fracture risk, even after deficiency correction, according to the National Institutes of Health 1
Continue calcium supplementation of 1,000-1,500 mg daily indefinitely to support ongoing bone health, as recommended by the National Osteoporosis Foundation 1

Never use active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) to treat nutritional vitamin D deficiency, as they bypass normal regulatory mechanisms, do not correct 25(OH)D levels, and carry higher risk of hypercalcemia, according to the Endocrine Society 1
Avoid single ultra-high loading doses exceeding 300,000 IU, as they have been shown to be inefficient or potentially harmful for fall and fracture prevention, as suggested by the National Institutes of Health 1
Do not rely on calcium and vitamin D supplementation alone for established osteoporosis with bone deformities—these patients require comprehensive osteoporosis management including consideration of antiresorptive therapy, according to the National Osteoporosis Foundation 3